NCT02997774

Brief Summary

Having hemodialysis affects the blood supply to various organs in the body including the heart and the brain. With time, these effects build up and can affect the way these organs function. The investigators have previously shown that the liver (a key organ which works to help clean the blood, make proteins and turn all your food into energy) is also affected. One of the ways to help protect organs from injury due to dialysis has been cooling during dialysis. The investigators want to examine whether cooling during dialysis protects the blood supply to the liver. CT imaging will be used to measure this blood supply during hemodialysis with standard and cooler settings.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 16, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 20, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

February 8, 2017

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 4, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 4, 2018

Completed
Last Updated

August 17, 2018

Status Verified

August 1, 2018

Enrollment Period

1.2 years

First QC Date

December 16, 2016

Last Update Submit

August 16, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in regional liver perfusion in mls/min/100g from baseline to peak stress during dialysis (3 hours into the dialysis session) with standard versus cooler dialysate temperature.

    2 years

Secondary Outcomes (8)

  • Change in global liver perfusion in mls/min/100g pre, during and post-dialysis with cooler dialysate

    2 years

  • ICG clearance rate pre, during and post-dialysis with cooler vs standard dialysate

    2 years

  • Contribution of portal venous flow to hepatic perfusion (PV fraction) pre, during and post-dialysis with cooler vs standard dialysate

    2 years

  • Endotoxin levels with cooler vs standard dialysate

    2 years

  • Troponin T levels with cooler vs standard dialysate

    2 years

  • +3 more secondary outcomes

Study Arms (2)

Standard Dialysis

ACTIVE COMPARATOR

Patient will undergo dialysis at 36.5 degrees Celsius to assess if this affects the liver function and perfusion

Other: Standard Dialysis

Cooler Dialysis

EXPERIMENTAL

Patient will undergo dialysis at 35 degrees Celsius to assess if this affects the liver function and perfusion

Other: Cooler dialysis

Interventions

Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)

Cooler Dialysis

Having dialysis at a standard temperature (36.5 degrees Celsius)

Standard Dialysis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Be able to provide informed consent
  • Age greater than 18 years
  • Hemodialysis for at least 3 months
  • No significant residual renal function (\<250mls urine/day)

You may not qualify if:

  • Chronic liver disease of any stage
  • Chronic intestinal disease excluding Irritable Bowel Syndrome (IBS)
  • Previous liver transplant or liver resection
  • Previous Transjugular Portosystemic Shunt (TIPSS) insertion
  • Active infection or malignancy
  • Pregnant, breastfeeding or intending pregnancy
  • Unable to give consent or understand written information
  • Diabetic and experiencing hypoglycemia during dialysis within the last 2 months
  • Known allergy/intolerance to contrast agent or iodides

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

London Health Sciences Centre

London, Ontario, Canada

Location

Study Officials

  • Chris W McIntyre, PhD

    Western University, Canada

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Neither subjects nor the investigator at the study visits will be blinded; however, analysis of imaging data will be performed with the operator blinded to allocation.
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor of Medicine, UWO

Study Record Dates

First Submitted

December 16, 2016

First Posted

December 20, 2016

Study Start

February 8, 2017

Primary Completion

May 4, 2018

Study Completion

May 4, 2018

Last Updated

August 17, 2018

Record last verified: 2018-08

Data Sharing

IPD Sharing
Will not share

Locations